Experts review different treatment delivery options available for the management of non–muscle-invasive bladder cancer (NMIBC), discuss the exciting developments in NMIBC with several delivery systems ...

Panelists discuss how the PEACE-3 trial demonstrated meaningful clinical benefits with the combination of radium-223 and enzalutamide compared with enzalutamide alone in patients with metastatic ...

Panelists discuss how the combination of radium-223 and enzalutamide (RAD-ENZ) demonstrated a manageable safety profile in PEACE-3, with bone health monitoring and prophylactic bone-targeted therapy ...

"[Urologists] really need to understand how big the prostate is and how big of a surgery that they're looking at," says Amy E. Krambeck, MD. In this video, Amy E. Krambeck, MD, shares her perspective ...

The updated guideline includes 25 recommendations, emphasizing risk stratification and minimizing unnecessary evaluations for low-risk patients. New guidance incorporates urine-based tumor markers for ...

On January 28, 2025, and February 25, 2025, Urology Times conducted case-based roundtable discussions on the topic of upper tract urothelial cancer (UTUC). The programs were moderated by Katie S.

Experts discuss the standard of care and the use of intravesical chemotherapy in the treatment of non–muscle-invasive bladder cancer (NMIBC).

“In the setting of widespread metastatic progression or failure, we typically prefer more systemic therapy with metastasis-directed therapy for symptomatic sites,” says Kate H. Gessner, MD, PhD. In ...

“The primary end point is progression-free survival, and the secondary end points are overall survival, objective response rates, duration of response, and safety.” In this video, Francesca ...

Panelists discuss how radiopharmaceuticals like lutetium-177 prostate-specific membrane antigen (PSMA) may be preferred over systemic therapy in patients with prostate cancer who have high PSMA ...

ABO-101 received orphan drug and rare pediatric disease designations for PH1, targeting the HAO1 gene to reduce oxalate production. Ibex Prostate Detect, an AI-powered diagnostic tool, achieved 510(k) ...

"I'm always trying new things. I feel like, once you decide that this is the way you have to do it and stick with that forever, that's when you immediately become irrelevant," says Amy E. Krambeck, MD ...